INTRODUCTION
Gastric cancer, multiple cancer, anti‐angiogenesis, cancer, deaths
GASTRIC CANCER, CANCER, MULTIPLE CANCER, METASTASIS
Gastric cancer (GC) is the fifth most common type of cancer and represents the fourth leading cause of cancer‐related deaths worldwide.Although there is no single standard cytotoxic chemotherapy regimen for metastatic or unresectable GC, fluoropyrimidine and platinum‐containing doublet or triplet regimens are the standard first‐line chemotherapy.Angiogenesis is fundamental for the growth of cancer and vascular metastasis. Therefore, anti‐angiogenesis is a major target for the treatment of multiple cancer types. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF‐A), in combination with XP, was tested as front‐line treatment in a randomized phase III trial (AVAGAST).Sorafenib is a multi‐kinase inhibitor of the VEGFR and RAF–MEK–ERK pathways that have anti‐angiogenic activityWe previously performed a phase I dose‐finding study of sorafenib plus XP (S + XP). The recommended dose of S + XP for chemotherapy‐naive patients with GC was sorafenib (400 mg bid, D1‐21), capecitabine (800 mg/m